ArticleInfection and drug resistance2025
A Comparison of Mortality, Readmissions, and Outcomes in Injection Drug Use-Associated Infective Endocarditis Caused by Methicillin-Resistant Versus Methicillin-Susceptible
Article in Infection and drug resistance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The global epidemiology of MRSA.JAC-antimicrobial resistance · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aimed to compare mortality and outcomes among patients with injection drug use (IDU)-associated infective endocarditis (IE) caused by MRSA (methicillin-resistant Patients and Methods: A single-center retrospective cohort study was performed on adult patients (≥18 years old) at a large academic medical center in the Mid-Southern United States of America between January 2013 and January 2020 to compare the mortality and outcomes of initial cases of IDU-associated IE due to MRSA and MSSA. All cases were confirmed using the Duke criteria for IE. Results: A total of 175 IE patients were divided into two groups based on the causative agent: MRSA and MSSA. A total of 25 patients (14.3%) died during the index hospitalization, while 34 (19.4%) died within one year of index hospitalization. We observed no statistically significant differences between MRSA IE and MSSA IE in terms of mortality, intensive care unit admissions, hospital readmission rates, IE recurrence, or surgical intervention. The major difference between the two groups was the significantly higher rate of septic pulmonary emboli in the MRSA IE group than in the MSSA IE group ( Conclusion: Our study affirms the overall severity and high mortality rate of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.